Kaplan-Meier analysis evaluating patient overall survival (OS) with prestratification by tumor measurements (2D and 3D) and substratification by treatment group. There is significant separation in OS between the Bev groups (Bev or Bev/CCNU) and CCNU 01-04 among all patients with large tumor size, 2D and 3D measurement, respectively (Figure 3A and 3C). Such separation was not observed among patients with small tumor sizes, 2D and 3D measurement, respectively (Figure 3B and 3D). 2D indicates 2-dimensional; 3D, 3-dimensional; Bev, bevacizumab; CCNU, lomustine.